Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[age]	Characteristics[developmental stage]	Characteristics[sex]	Characteristics[ancestry category]	Characteristics[disease]	Characteristics[cell type]	Characteristics[cell line]	Characteristics[treatment]	Characteristics[treatment]	Characteristics[enrichment method]	Characteristics[enrichment process]	Material Type	assay name	Technology Type	comment[label]	comment[file uri]	comment[fractionation method]	comment[fraction identifier]	comment[instrument]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[cleavage agent details]	comment[cleavage agent details]	comment[fragment mass tolerance]	comment[precursor mass tolerance]	comment[data file]	factor value[enrichment process]	factor value[treatment]	factor value[treatment]
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 1	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 1	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 1	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 2	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 2	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 2	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 3	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 3	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 3	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 4	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 4	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 4	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 5	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 5	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 5	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 6	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 6	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 6	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 7	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 7	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 7	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 8	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 8	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 8	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 9	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 9	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 9	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 10	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 10	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 10	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 11	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 11	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 11	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 12	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 12	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 12	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 13	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 13	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 13	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 14	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 14	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 14	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 15	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 15	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 15	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 16	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 16	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 16	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 17	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 17	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 17	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 18	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 18	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 18	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 19	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 19	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 19	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 20	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 20	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 20	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 21	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 21	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 21	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 22	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 22	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 22	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 23	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 23	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 23	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 24	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 24	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 24	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 25	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 25	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 25	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 26	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 26	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 26	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 27	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 27	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 27	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 28	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 28	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 28	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 29	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 29	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 29	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 30	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 30	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 30	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 31	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 31	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 31	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 32	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 32	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 32	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 33	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 33	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 33	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 34	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 34	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 34	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 35	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 35	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 35	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 36	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 36	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 36	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 37	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 37	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 37	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 38	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 38	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 38	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 39	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 39	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 39	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 40	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 40	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 40	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 41	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 41	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 41	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 42	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 42	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 42	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 43	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 43	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 43	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 44	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 44	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 44	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 45	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 45	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 45	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 46	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 46	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 46	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 47	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 47	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 47	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 48	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 48	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 48	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 49	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	cell	run 49	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 49	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 50	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 50	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 50	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 51	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 51	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 51	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 52	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 52	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 52	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 53	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 53	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 53	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 54	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 54	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 54	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 55	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 55	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 55	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 56	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	cell	run 56	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 56	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 57	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 57	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 57	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 58	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 58	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 58	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 59	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 59	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 59	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 60	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 60	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 60	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 61	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 61	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 61	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 62	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 62	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 62	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 63	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 63	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 63	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 64	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 64	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 64	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 65	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 65	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 65	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 66	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 66	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 66	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 67	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 67	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 67	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 68	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 68	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 68	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 69	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 69	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 69	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 70	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 70	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 70	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 71	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 71	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 71	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 72	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 72	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 72	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 73	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 73	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 73	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 74	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 74	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 74	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 75	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 75	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 75	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 76	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 76	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 76	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 77	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 77	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 77	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 78	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 78	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 78	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 79	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 79	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 79	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 80	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 80	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 80	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 81	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 81	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 81	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 82	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 82	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 82	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 83	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 83	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 83	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 84	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 84	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 84	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 85	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 85	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 85	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 86	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 86	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 86	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 87	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 87	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 87	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 88	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 88	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 88	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 89	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 89	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 89	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 90	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 90	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 90	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 91	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 91	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 91	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 92	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 92	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 92	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 93	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 93	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 93	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 94	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 94	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 94	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 95	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 95	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 95	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 96	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 96	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 96	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 97	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 97	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 97	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 98	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 98	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 98	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 99	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	cell	run 99	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 99	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	no enrichment	none	control
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 100	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 100	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 100	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	no enrichment	none	control
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 101	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 101	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 101	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 102	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 102	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 102	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 103	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 103	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 103	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 104	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 104	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 104	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 105	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 105	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 105	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 106	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 106	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 106	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 107	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 107	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 107	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 108	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 108	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 108	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 109	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 109	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 109	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 110	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 110	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 110	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 111	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	cell	run 111	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 111	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 112	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 112	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 112	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 113	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 113	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 113	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 114	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 114	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 114	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 115	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 115	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 115	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 116	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 116	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 116	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 117	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	cell	run 117	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	cell	run 117	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	no enrichment	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 118	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 118	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 118	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 119	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 119	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 119	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 120	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 120	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 120	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 121	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 121	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 121	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 122	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 122	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 122	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 123	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 123	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 123	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 124	proteomic profiling by mass spectrometry	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	cell	run 124	proteomic profiling by mass spectrometry	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	cell	run 124	proteomic profiling by mass spectrometry	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	enrichment of phosphorylated Protein	none	control
